IDH1/2 LNA-qPCR MRD has the potential to become a clinical tool to monitor deep treatment response and predict relapse for IDH1/2 mutated AML patients, especially for those who are younger, with reduced IDH1/2 MRD at first CR, or concurrent FLT3 mutation. This evidence concerns the gene FLT3 and acute myeloid leukemia.